Tag: glioblastoma multiforme market outlook

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Glioblastoma Multiforme Market Revenue Growth Supported By A CAGR Of 3.93% Through 2030

The market for glioblastoma multiforme treatments experienced a significant expansion recently, and this upward trajectory is projected to continue. It is anticipated to grow from $2.7 billion in 2025 to $2.92 billion in 2026, reflecting a compound annual growth rate of 8.1%. Factors contributing to this expansion in the past include a scarcity of therapeutic choices, progress in the field of neuro-oncology, the establishment of standardized chemotherapy protocols, an increase in cancer research facilities, and enhancements in medical imaging capabilities.

The glioblastoma multiforme sector is poised for considerable expansion in the upcoming years, projected to reach a valuation of $3.94 billion by 2030, driven by a compound annual growth rate of 7.8%. This anticipated growth stems from advancements in the creation of innovative targeted pharmaceuticals, intensified immunotherapy research initiatives, the increasing embrace of individualized cancer therapies, augmented financial investment in brain cancer studies, and a heightened emphasis on enhancing patient survival rates. Key developments shaping the forecast period involve a greater concentration on specific cancer treatments, a surge in the utilization of diverse therapeutic strategies, the broadening scope of precision oncology investigations, a growing deployment of sophisticated diagnostic imaging techniques, and an overall improvement in engagement with clinical trials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

Glioblastoma Multiforme Market Growth Factors Supporting Long-Term Expansion

The escalating prevalence of brain disorders is poised to be a primary catalyst for the glioblastoma multiforme market’s expansion. Conditions affecting brain structure or function, resulting in impairments in cognitive, emotional, or physical capabilities, are increasingly observed. Factors contributing to this surge include an aging demographic, extended lifespans, evolving lifestyle patterns, and enhanced diagnostic technologies. Investigating these neurological conditions facilitates progress in glioblastoma multiforme (GBM) research, paving the way for earlier detection, novel therapeutic interventions, and enhanced patient prognoses. Such research efforts can illuminate the genetic and molecular pathways implicated in GBM’s onset. As an illustration, Dementia Australia reported in February 2025 that roughly 433,300 individuals in Australia are currently affected by dementia, a figure predicted to ascend to 812,500 by 2054. Furthermore, dementia commencing at a younger age impacts approximately 29,000 individuals in 2025, with estimates suggesting this number will climb to 41,000 by 2054. Consequently, the growing incidence of brain disorders is a significant driver for the glioblastoma multiforme market.

Glioblastoma Multiforme Market Segment Analysis Highlighting Growth Areas

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Glioblastoma Multiforme Market Industry Trends Shaping Future Revenue Growth

In the glioblastoma multiforme sector, leading entities are directing their efforts towards pioneering innovative treatments, specifically CAR T-cell therapies, in an endeavor to meet the significant unmet medical requirements presented by this aggressive form of cancer. This immunotherapy approach entails the genetic alteration of a patient’s own T-cells, equipping them with the capability to more precisely identify and eradicate malignant cells. Illustrating this trend, Chimeric Therapeutics Limited, a biotechnology firm situated in Australia, initiated a Phase IB clinical investigation in June 2023 for its CHM 1101 (CLXT CAR T) treatment, targeting patients experiencing recurrent or advancing glioblastoma multiforme (GBM). This multi-center study is designed to thoroughly assess the treatment’s safety profile and effectiveness, concurrently establishing the optimal dosage for subsequent Phase 2 studies. Positive preliminary findings from the Phase 1a stage indicated disease stabilization, and this new trial seeks to leverage those early successes to propel the therapy towards broader clinical application. The company intends to utilize the gathered evidence to formulate the design for a pivotal registration trial and solicit guidance from regulatory bodies.

Glioblastoma Multiforme Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Access The Complete Glioblastoma Multiforme Market Report:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Glioblastoma Multiforme Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the glioblastoma multiforme market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Glioblastoma Multiforme Market Revenue Growth Supported By A CAGR Of 3.93% Through 2030

The market for glioblastoma multiforme treatments experienced a significant expansion recently, and this upward trajectory is projected to continue. It is anticipated to grow from $2.7 billion in 2025 to $2.92 billion in 2026, reflecting a compound annual growth rate of 8.1%. Factors contributing to this expansion in the past include a scarcity of therapeutic choices, progress in the field of neuro-oncology, the establishment of standardized chemotherapy protocols, an increase in cancer research facilities, and enhancements in medical imaging capabilities.

The glioblastoma multiforme sector is poised for considerable expansion in the upcoming years, projected to reach a valuation of $3.94 billion by 2030, driven by a compound annual growth rate of 7.8%. This anticipated growth stems from advancements in the creation of innovative targeted pharmaceuticals, intensified immunotherapy research initiatives, the increasing embrace of individualized cancer therapies, augmented financial investment in brain cancer studies, and a heightened emphasis on enhancing patient survival rates. Key developments shaping the forecast period involve a greater concentration on specific cancer treatments, a surge in the utilization of diverse therapeutic strategies, the broadening scope of precision oncology investigations, a growing deployment of sophisticated diagnostic imaging techniques, and an overall improvement in engagement with clinical trials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

Glioblastoma Multiforme Market Growth Factors Supporting Long-Term Expansion

The escalating prevalence of brain disorders is poised to be a primary catalyst for the glioblastoma multiforme market’s expansion. Conditions affecting brain structure or function, resulting in impairments in cognitive, emotional, or physical capabilities, are increasingly observed. Factors contributing to this surge include an aging demographic, extended lifespans, evolving lifestyle patterns, and enhanced diagnostic technologies. Investigating these neurological conditions facilitates progress in glioblastoma multiforme (GBM) research, paving the way for earlier detection, novel therapeutic interventions, and enhanced patient prognoses. Such research efforts can illuminate the genetic and molecular pathways implicated in GBM’s onset. As an illustration, Dementia Australia reported in February 2025 that roughly 433,300 individuals in Australia are currently affected by dementia, a figure predicted to ascend to 812,500 by 2054. Furthermore, dementia commencing at a younger age impacts approximately 29,000 individuals in 2025, with estimates suggesting this number will climb to 41,000 by 2054. Consequently, the growing incidence of brain disorders is a significant driver for the glioblastoma multiforme market.

Glioblastoma Multiforme Market Segment Analysis Highlighting Growth Areas

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Glioblastoma Multiforme Market Industry Trends Shaping Future Revenue Growth

In the glioblastoma multiforme sector, leading entities are directing their efforts towards pioneering innovative treatments, specifically CAR T-cell therapies, in an endeavor to meet the significant unmet medical requirements presented by this aggressive form of cancer. This immunotherapy approach entails the genetic alteration of a patient’s own T-cells, equipping them with the capability to more precisely identify and eradicate malignant cells. Illustrating this trend, Chimeric Therapeutics Limited, a biotechnology firm situated in Australia, initiated a Phase IB clinical investigation in June 2023 for its CHM 1101 (CLXT CAR T) treatment, targeting patients experiencing recurrent or advancing glioblastoma multiforme (GBM). This multi-center study is designed to thoroughly assess the treatment’s safety profile and effectiveness, concurrently establishing the optimal dosage for subsequent Phase 2 studies. Positive preliminary findings from the Phase 1a stage indicated disease stabilization, and this new trial seeks to leverage those early successes to propel the therapy towards broader clinical application. The company intends to utilize the gathered evidence to formulate the design for a pivotal registration trial and solicit guidance from regulatory bodies.

Glioblastoma Multiforme Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Access The Complete Glioblastoma Multiforme Market Report:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Glioblastoma Multiforme Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the glioblastoma multiforme market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Glioblastoma Multiforme Market Revenue Growth Supported By A CAGR Of 3.93% Through 2030

The market for glioblastoma multiforme treatments experienced a significant expansion recently, and this upward trajectory is projected to continue. It is anticipated to grow from $2.7 billion in 2025 to $2.92 billion in 2026, reflecting a compound annual growth rate of 8.1%. Factors contributing to this expansion in the past include a scarcity of therapeutic choices, progress in the field of neuro-oncology, the establishment of standardized chemotherapy protocols, an increase in cancer research facilities, and enhancements in medical imaging capabilities.

The glioblastoma multiforme sector is poised for considerable expansion in the upcoming years, projected to reach a valuation of $3.94 billion by 2030, driven by a compound annual growth rate of 7.8%. This anticipated growth stems from advancements in the creation of innovative targeted pharmaceuticals, intensified immunotherapy research initiatives, the increasing embrace of individualized cancer therapies, augmented financial investment in brain cancer studies, and a heightened emphasis on enhancing patient survival rates. Key developments shaping the forecast period involve a greater concentration on specific cancer treatments, a surge in the utilization of diverse therapeutic strategies, the broadening scope of precision oncology investigations, a growing deployment of sophisticated diagnostic imaging techniques, and an overall improvement in engagement with clinical trials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

Glioblastoma Multiforme Market Growth Factors Supporting Long-Term Expansion

The escalating prevalence of brain disorders is poised to be a primary catalyst for the glioblastoma multiforme market’s expansion. Conditions affecting brain structure or function, resulting in impairments in cognitive, emotional, or physical capabilities, are increasingly observed. Factors contributing to this surge include an aging demographic, extended lifespans, evolving lifestyle patterns, and enhanced diagnostic technologies. Investigating these neurological conditions facilitates progress in glioblastoma multiforme (GBM) research, paving the way for earlier detection, novel therapeutic interventions, and enhanced patient prognoses. Such research efforts can illuminate the genetic and molecular pathways implicated in GBM’s onset. As an illustration, Dementia Australia reported in February 2025 that roughly 433,300 individuals in Australia are currently affected by dementia, a figure predicted to ascend to 812,500 by 2054. Furthermore, dementia commencing at a younger age impacts approximately 29,000 individuals in 2025, with estimates suggesting this number will climb to 41,000 by 2054. Consequently, the growing incidence of brain disorders is a significant driver for the glioblastoma multiforme market.

Glioblastoma Multiforme Market Segment Analysis Highlighting Growth Areas

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Glioblastoma Multiforme Market Industry Trends Shaping Future Revenue Growth

In the glioblastoma multiforme sector, leading entities are directing their efforts towards pioneering innovative treatments, specifically CAR T-cell therapies, in an endeavor to meet the significant unmet medical requirements presented by this aggressive form of cancer. This immunotherapy approach entails the genetic alteration of a patient’s own T-cells, equipping them with the capability to more precisely identify and eradicate malignant cells. Illustrating this trend, Chimeric Therapeutics Limited, a biotechnology firm situated in Australia, initiated a Phase IB clinical investigation in June 2023 for its CHM 1101 (CLXT CAR T) treatment, targeting patients experiencing recurrent or advancing glioblastoma multiforme (GBM). This multi-center study is designed to thoroughly assess the treatment’s safety profile and effectiveness, concurrently establishing the optimal dosage for subsequent Phase 2 studies. Positive preliminary findings from the Phase 1a stage indicated disease stabilization, and this new trial seeks to leverage those early successes to propel the therapy towards broader clinical application. The company intends to utilize the gathered evidence to formulate the design for a pivotal registration trial and solicit guidance from regulatory bodies.

Glioblastoma Multiforme Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Access The Complete Glioblastoma Multiforme Market Report:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Glioblastoma Multiforme Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the glioblastoma multiforme market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Glioblastoma Multiforme Market Expected To Reach Based On Its 2026 Value?

The glioblastoma multiforme market size has seen robust growth over the past few years. It is anticipated to increase from $2.7 billion in 2025 to $2.92 billion in 2026, registering a compound annual growth rate (CAGR) of 8.1%. This historical expansion can be attributed to factors such as limited treatment options, developments in neuro-oncology, the standardization of chemotherapy, an increase in cancer research centers, and improvements in imaging technologies.

The glioblastoma multiforme market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $3.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period is primarily driven by factors such as the emergence of innovative targeted pharmaceuticals, the broadening scope of immunotherapy investigations, the integration of individualized cancer therapies, enhanced financial support for brain cancer studies, and a sharpened emphasis on improving patient survival rates. Key trends expected throughout this period encompass a heightened concentration on targeted cancer treatments, the increasing implementation of multi-modal therapeutic strategies, the advancement of precision oncology studies, the wider integration of sophisticated imaging diagnostics, and improved engagement in clinical trials.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Key Factors Are Driving The Glioblastoma Multiforme Market Growth?

The growing prevalence of brain disorder cases is projected to drive the glioblastoma multiforme market moving forward. A brain disorder is defined as a condition impacting the brain’s structure or function, leading to cognitive, emotional, or physical impairments. The increase in brain disorder instances is attributed to factors such as aging demographics, extended life expectancy, lifestyle choices, and advancements in diagnostic capabilities. A deeper understanding of brain disorders aids in advancing research on glioblastoma multiforme (GBM), resulting in enhanced early detection, innovative treatment options, and improved patient outcomes. By examining neurological conditions, scientists can discover genetic and molecular correlations that contribute to GBM development. For example, in February 2025, as reported by Dementia Australia, an Australia-based non-profit organization, roughly 433,300 Australians are living with dementia, and this figure is expected to surge to 812,500 by 2054. Moreover, younger-onset dementia affects approximately 29,000 people in 2025, with forecasts suggesting an escalation to 41,000 by 2054. Hence, the increasing number of brain disorder cases will fuel the growth of the glioblastoma multiforme market.

Which Segments Define The Glioblastoma Multiforme Market Segment Structure?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Which Trends Are Guiding The Direction Of The Glioblastoma Multiforme Market?

Key companies operating in the glioblastoma multiforme market are concentrating on developing advanced treatments, such as CAR T-cell therapies, to address critical unmet medical needs in aggressive cancer. CAR T-cell therapies are a type of immunotherapy that involves modifying a patient’s T-cells to more effectively target and eliminate cancer cells. For instance, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, initiated a Phase IB clinical trial for its CHM 1101 (CLXT CAR T) therapy, intended for recurrent or progressive glioblastoma multiforme (GBM). This multi-center trial aims to assess the therapy’s safety and efficacy, while also determining the recommended Phase 2 dose. Initial Phase 1a results demonstrated disease stability, and the current trial will expand upon these findings to support continued development. The company intends to leverage this data to design a registration trial and obtain regulatory feedback.

Who Are The Established Players Within The Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Get The Full Glioblastoma Multiforme Market Report:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Region Is The Top Contributor To The Glioblastoma Multiforme Market By Share?

North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Glioblastoma Multiforme Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2026, By The Business Research Company

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Glioblastoma Multiforme Gbm Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Glioma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Glioblastoma Multiforme Market By 2030 Starting From Its 2026 Size?

The glioblastoma multiforme market has shown significant expansion in recent years. It is forecast to increase from $2.7 billion in 2025 to $2.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. Historically, this growth was driven by factors such as limited treatment options, advancements within neuro-oncology, the standardization of chemotherapy, the proliferation of cancer research centers, and improvements in imaging technologies.

The market for glioblastoma multiforme is projected to experience substantial expansion in the coming years, with its valuation anticipated to reach $3.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. Key factors contributing to this projected growth include the innovation of new targeted medications, an increase in immunotherapy research, the uptake of personalized cancer therapies, enhanced financial support for brain cancer studies, and a greater emphasis on improving patient survival rates. Significant trends expected during this period involve a heightened concentration on targeted cancer treatments, the increasing implementation of multi-modal therapeutic strategies, the broadening scope of precision oncology investigations, the wider integration of sophisticated imaging diagnostics, and improved engagement in clinical trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Glioblastoma Multiforme Market?

The glioblastoma multiforme market is anticipated to be driven by the increasing prevalence of brain disorder cases. A brain disorder is defined as a condition affecting the brain’s structure or function, resulting in cognitive, emotional, or physical challenges. The escalation in brain disorder cases is attributable to elements like aging populations, longer life expectancies, lifestyle choices, and improved diagnostic capabilities. Gaining insights into brain disorders aids in advancing research on glioblastoma multiforme (GBM), fostering better early detection, innovative therapies, and improved patient results. By studying various neurological conditions, scientists are able to uncover genetic and molecular connections that contribute to GBM development. For example, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, an estimated 433,300 Australians are living with dementia, with this figure projected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Consequently, the rising instances of brain disorders will propel the growth of the glioblastoma multiforme market.

Which Segment Categories Define The Glioblastoma Multiforme Market?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

What Trends Are Projected To Affect The Glioblastoma Multiforme Market?

Major companies engaged in the glioblastoma multiforme market are concentrating on the development of advanced therapies, such as CAR T-cell therapies, to meet the unmet medical needs associated with aggressive cancer. CAR T-cell therapies are a form of immunotherapy that involves genetically modifying a patient’s T-cells to more effectively target and eradicate cancer cells. For example, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech firm, initiated a Phase IB clinical trial for its CHM 1101 (CLXT CAR T) therapy for individuals with recurrent or progressive glioblastoma multiforme (GBM). The trial, which is being conducted across multiple centers, aims to assess the therapy’s safety and efficacy while also determining the appropriate Phase 2 dose. Initial results from Phase 1a demonstrated disease stability, and the current trial will build upon these findings to support further development. The company plans to use the collected data to inform the design of a registration trial and seek feedback from regulatory authorities.

Who Are The Top Companies Competing In The Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Read the full glioblastoma multiforme market report here:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Regions Are Projected To Dominate The Glioblastoma Multiforme Market In The Coming Years?

North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Glioblastoma Multiforme Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp

Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2026, By The Business Research Company

Minimally Invasive Glaucoma Surgery Migs Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/minimally-invasive-glaucoma-surgery-migs-devices-global-market-report

Eye Melanoma Global Market Report

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Optic Atrophy Management Global Market Report

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model